lixisenatide (adlyxin) Report issue

Biologics Peptide Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lixisenatide (trade name Adlyxin) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$214.5700
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( insulin glargine (toujeo), lixisenatide (adlyxin) - other name: insulin glargine and lixisenatide )

Alternative names

adlyxin | aqve-10010 | ave0010 | ave 0010 | ave-0010 | ave 010 | ave-010 | des-38-proline-exendine-4 (heloderma suspectum)-(1-39)-peptidylpenta-l-lysyl-l-lysinamide | despro38exendin-4(1-39)-lys6-nh2 | iglarlixi | insulin glargine / lixisenatide | l-histidylglycyl-l-α-glutamylglycyl-l-threonyl-l-phenylalanyl-l-threonyl-l-seryl-l-α-aspartyl-l-leucyl-l-seryl-l-lysyl-l-glutaminyl-l-methionyl-l-α-glutamyl-l-α-glutamyl-l-α-glutamyl-l-alanyl-l-valyl-l-arginyl-l-leucyl-l-phenylalanyl-l-isoleucyl-l-α-glutamyl-l-tryptophyl-l-leucyl-l-lysyl-l-asparaginylglycylglycyl-l-prolyl-l-seryl-l-serylglycyl-l-alanyl-l-prolyl-l-prolyl-l-seryl-l-lysyl-l-lysyl-l-lysyl-l-lysyl-l-lysyl-l-lysinamide | lixisenatida | lixisenatide | lixisénatide | lyxumia | zp 10 | zp-10 | zp10a peptide

Organizations (21)

Research & Development (20)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Acute Coronary Syndrome (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 1)

Diabetes Mellitus, Type 2 ()

Diabetic Nephropathies (Phase 4)

Gastroparesis (Phase 1/Phase 2)

Glucagon-Like Peptide 1 (Phase 4)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 58
  • # of Trial Organizations: 20

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue